Understanding how BRCA2 and RAD51 affect cancer treatment response
Defining the Roles of BRCA2 and RAD51 in PARPi Response
['FUNDING_R01'] · YALE UNIVERSITY · NIH-11078824
This study is looking at how changes in the BRCA2 gene affect how well a cancer treatment called PARP inhibitors works, so we can better understand which patients with breast and other cancers might benefit from this therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11078824 on ClinicalTrials.gov |
What this research studies
This research investigates how mutations in the BRCA2 gene influence the effectiveness of PARP inhibitors, a type of cancer therapy. By using advanced biochemical and cellular assays, the study aims to uncover the mechanisms behind how these drugs kill cancer cells that lack functional BRCA genes while sparing normal cells. The goal is to identify which patients are likely to respond to PARP inhibitors based on their specific BRCA mutations, ultimately improving treatment outcomes for those with breast and other cancers linked to BRCA mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast or other cancers who have known BRCA1 or BRCA2 mutations.
Not a fit: Patients without BRCA mutations or those with cancers not related to BRCA genes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective cancer treatments for patients with BRCA mutations.
How similar studies have performed: Previous research has shown promising results in understanding the role of BRCA mutations in cancer therapy, making this approach both relevant and potentially impactful.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JENSEN, RYAN BROWN — YALE UNIVERSITY
- Study coordinator: JENSEN, RYAN BROWN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy